Starling Oncology, Inc. (STLNW) Operating income 2020–2025
Starling Oncology, Inc. (STLNW) annual operating income history from SEC filings — each fiscal year as reported.
-$36.1MFY2025 · since FY2020: -$8.2M → -$36.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$36.1M | +40.0% |
| FY2024 | -$60.1M | +21.9% |
| FY2023 | -$77.0M | +6.0% |
| FY2022 | -$82.0M | -78.7% |
| FY2021 | -$45.9M | -459.4% |
| FY2020 | -$8.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating marginSTLNW Operating cash flowSTLNW Free cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →